{
  "title": "Lovastatin Therapy in Rheumatoid Arthritis",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY473",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Lovastatin Therapy in Rheumatoid Arthritis",
  "performedBy": [
    {
      "firstName": "Cynthia",
      "lastName": "Aranow",
      "email": "caranow@nshs.edu",
      "affiliations": [
          {
             "name": "Feinstein Institute for Medical Research NS-LIJ Health System"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "firstName": "Betty",
      "lastName": "Diamond",
      "email": "bdiamond@nshs.edu",
      "affiliations": [
          {
             "name": "Feinstein Institute for Medical Research NS-LIJ Health System"
          }
      ],
      "roles": [
          {
             "value": "Co-Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "Lovastatin",
          "size": 34
        },
        {
          "name": "Placebo",
          "size": 30
        }
  ],
  
  "usesReagent": [
        {
          "name": "Mip1a"
        },
        {
          "name": "G-CSF"
        },
        {
          "name": "IFNG"
        },
        {
          "name": "IL1B"
        },
        {
          "name": "ICAM"
        },
        {
          "name": "IL-6"
        },
        {
          "name": "OPG"
        },
        {
          "name": "VCAM1"
        },
        {
          "name": "IL-12p70"
        },
        {
          "name": "IL-10"
        },
        {
          "name": "IL-17A"
        },
        {
          "name": "RANTES"
        },
        {
          "name": "TNF"
        },
        {
          "name": "RANKL"
        },
        {
          "name": "MCP-1"
        },
        {
          "name": "IL-1Ra"
        },
        {
          "name": "E-Selectin"
        },
        {
          "name": "BAFF"
        },
        {
          "name": "human IgG Fc fragment"
        },
        {
          "name": "peroxidase conjugated goat F(ab')2 anti-human IgM"
        },
        {
          "name": "QUANTA Lite anti-CCP assay"
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Inclusion",
          "values": [
              "Informed about the study and signed an informed consent prior to performance of any study related procedures."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Diagnosed with RA as defined by the ACR 1987 Criteria for the Classification of Rheumatoid Arthritis"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Functional Class I, II, or III as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Serum CRP measurement of greater than 5 mg/L."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Mildly active disease at screening defined as follows (note, disease activity may change between screening and randomization,): At least 1 swollen (max 6) and 2 tender (max 8) joints"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If on corticosteroids, the dose must be stable and less than or equal to 10mg/day (prednisone or equivalent) for at least 4 weeks."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If on a DMARD (traditional or biologic), the dose must be stable i.e.: a. methotrexate, leflunomide, azathioprine, etanercept, adalimumab or anakinra for at least 4 weeks; b. 3 months if on hydroxychloroquine, gold, or abatacept (Orencia)."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "18-70 years of age."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Functionally euthyroid."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If female and with reproductive potential, a serum pregnancy test at screening must be negative. Note: A female subject should be considered to have reproductive potential unless she has been permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) as documented by an operative note/report or is post menopausal (without menses for 12 consecutive months) as documented in the medical history."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Males or females with reproductive potential must practice effective measures of birth control."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Currently taking (or history of receiving within 12 weeks) a HMG-CoA reductase inhibitor (statin)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of an adverse reaction to a HMG-CoA reductase inhibitor (statin)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Active or recent infection within the previous 4 weeks."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Myositis or an unexplained elevation in CPK."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Joint replacement surgery within 60 days prior to study enrollment or planned within the course of the study."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Intra-articular cortisone injections within 4 weeks prior to study enrollment."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Pregnancy or lactation."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Chronic disorders apart from RA affecting the joints, such as systemic lupus erythematosus, psoriatic arthritis, gout, scleroderma or known reactive arthritis (i.e., Reiter?s syndrome)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Known infection with HIV."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with infliximab within 12 weeks of study enrollment."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with rituximab."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with medications metabolized using the cytochrome P3A4 pathway, such as cyclosporine, gemfibrozil, niacin, itraconazole, ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Investigational drug and/or treatment during the 4 weeks or seven half-lives of the investigational drug prior to the start of study drug dosing (Day 0), whichever is the greater length of time."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of alcohol abuse, history of liver disease and/or current liver disease (e.g., hepatitis, cirrhosis) or abnormal hepatic function (AST or ALT > 2 ULN)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Serum creatinine level > 1.5 mg/dL."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Seropositivity for hepatitis B surface antigen."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Seropositivity for hepatitis C antibody."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with amiodarone or verapamil."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any condition that, in the opinion of the Investigator, would jeopardize the subject?s safety following exposure to the study drug."
          ]
        }
  ],
  
  "types": [
      {
          "value": "Interventional"
      }
  ]
  },
  "creators": [
    {
      "firstName": "Cynthia",
      "lastName": "Aranow",
      "email": "caranow@nshs.edu",
      "affiliations": [
          {
             "name": "Feinstein Institute for Medical Research NS-LIJ Health System"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "LOVASTATIN THERAPY IN THE TREATMENT OF MILDLY ACTIVE RHEUMATOID ARTHRITIS (ARA02)",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "2M01RR018535-06"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "This study will look at the effects of a drug called lovastatin in the treatment of patients with mildly active rheumatoid arthritis (RA). Lovastatin is one of the 'statin' drugs approved by the FDA for the treatment of high cholesterol, but it is currently not approved for treating RA. There is evidence from laboratory studies that lovastatin may be beneficial in the treatment of mildly active RA. One purpose of this study is to determine if lovastatin is effective in reducing the inflammation that is seen in patients with mildly active RA. Another purpose is to see if it safe for treatment of mildly active RA. This study will look at the effects of lovastatin by comparing subjects with RA who are receiving the study drug, lovastatin, to those who do not. "
            }
          ]
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Interventional"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2006-08-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2015-09-18",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "Cytokine Quantification"
        },
        "description": "None",
        "types": [
            {
               "value": "Luminex xMAP"
            }
        ]
      },{
        "name": {
            "value": "Molecular Quantification"
        },
        "description": "None",
        "types": [
            {
               "value": "ELISA"
            }
        ]
      },{
        "name": {
            "value": "Molecular Quantification"
        },
        "description": "None",
        "types": [
            {
               "value": "ELISA"
            }
        ]
      },{
        "name": {
            "value": "Comprehensive Metabolic Panel"
        }
      },{
        "name": {
            "value": "Hematology test"
        }
      },{
        "name": {
            "value": "Supplemental Chemistry"
        }
      },{
        "name": {
            "value": "Fasting Lipid Profile"
        }
      },{
        "name": {
            "value": "Hormone measurement"
        }
      },{
        "name": {
            "value": "Enzyme measurement"
        }
      },{
        "name": {
            "value": "Immunology laboratory test"
        }
      }
      
  ],
  "isAbout": [
        {
          "name": "no treatment"
        }
  ],
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY473",
              "identifierSource": "ImmPort"
          },
          "title": "Lovastatin Therapy in Rheumatoid Arthritis",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY473",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "LOVASTATIN THERAPY IN THE TREATMENT OF MILDLY ACTIVE RHEUMATOID ARTHRITIS (ARA02)",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "None"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "Eighty adults will be enrolled in this study to evaluate lovastatin therapy in Rheumatoid Arthritis. Participants will receive 80 mg lovastatin po qd or 80 mg placebo po qd for twelve weeks."
}
